REGENCY: Obinutuzumab’s Promise for Lupus Nephritis
Update: 2025-02-28
Description
Join Dr Raquel Faria and Professors Richard Furie and Maria Dall’Era as they discuss the results of the phase 3 REGENCY trial of obinutuzumab for the treatment of lupus nephritis.This episode explores what obinutuzumab could mean for the future management of lupus nephritis.
Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
